ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-28 08:30 |
Abivax publie son calendrier financier 2025
|
French | 144.9 KB | ||
| 2025-01-28 08:30 |
Abivax Publishes 2025 Financial Calendar
|
English | 8.4 KB | ||
| 2025-01-27 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 97.2 KB | ||
| 2025-01-27 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 21.9 KB | ||
| 2025-01-24 22:05 |
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative C…
|
English | 12.1 KB | ||
| 2025-01-23 22:05 |
Abivax annonce la présentation de sept abstracts sur l'utilisation d’Obefazimod…
|
French | 245.0 KB | ||
| 2025-01-23 22:05 |
Abivax annonce la presentation de sept abstracts sur l'utilisation dObefazimod …
|
French | 47.9 KB | ||
| 2025-01-23 22:05 |
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative C…
|
English | 12.1 KB | ||
| 2025-01-10 17:35 |
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
|
English | 11.0 KB | ||
| 2025-01-09 17:44 |
Abivax franchit une étape clé dans le recrutement de l’essai de phase 3 ABTECT
|
French | 210.5 KB | ||
| 2025-01-09 17:44 |
Abivax franchit une etape cle dans le recrutement de lessai de phase 3 ABTECT
|
French | 30.7 KB | ||
| 2025-01-09 17:35 |
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
|
English | 11.0 KB | ||
| 2024-12-24 22:05 |
Abivax Announces a Change to the Composition of its Board of Directors
|
English | 9.3 KB | ||
| 2024-12-23 22:05 |
Abivax annonce une modification de la composition de son Conseil d'administrati…
|
French | 109.0 KB | ||
| 2024-12-23 22:05 |
Abivax Announces a Change to the Composition of its Board of Directors
|
English | 9.3 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
